Committee for ICSA Shanghai (Term 10/2013 to 10/2016)

Dejun Tang (Chair, Novartis, China, dejun.tang@novartis.com),

Zhi Geng (Peking University),

Chen Yao (Peking University),

Wei Yuan (Renmin University of China),

Qihua Wang (Chinese Academy of Sciences),

Guohua Zou (Chinese Academy of Sciences),

Hengjian Cui (Capital Normal University),

Zhaojun Wang (Nankai University),

Xiaolong Pu (East China Normal University),

Ming Zheng (Fudan University),

Naiqing Zhao (Fudan University),

Yong Zhou (Shanghai University of Finance and Economic),

Dong Han (Shanghai Jiao Tong University),

Huazhen Lin (Southwestern University of Finance and Economics,),

Xueqin Wang (Sun Yat-Sen University),

Feng Chen (Nanjing Medical University),

Jielai Xia (The Fourth Military Medical University),

Roger Qu (Pfizer, China),

Wei Zhang (Boehringer-Ingelheim, China),

Jie Chen (Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.),

Bill Wang (Merck, China),

Yanping Wang (Eli Lilly and Company, China),

Ouhong Wang (Amgen, China),

Jun Shao (University of Wisconsin/East China Normal University),

Dongchu Sun (University of Missouri/ East China Normal University), 

Zhezhen Jin (Ex-Officio,),

Wei Shen (Ex-Officio),

Mei-Ling Ting Lee (Ex-Officio)